---
figid: PMC5548615__nihms862090f2
figlink: /pmc/articles/PMC5548615/figure/F2/
number: F2
caption: PI3K/AKT pathway hyperactivation represents a viable therapeutic modality
  in cancer. The blue box indicates PI3K inhibitors with preclinical and/or clinical
  activity. Non-selective, “pan” PI3K inhibitors target all class I PI3K isoforms
  and p110α-selective inhibitors are biologically active against tumors with p110α
  hyperactivation through upstream RTK activation or direct p110α mutational activation.
  P110β-selective inhibitors are efficacious in the treatment of tumors characterized
  by PTEN genomic alteration, and the p110δ-selective inhibitor Idelalisib is effective
  in blocking PI3K-mediated B cell receptor signaling and is FDA approved for the
  treatment of relapsed chronic lymphoid leukemia (CLL). The purple box highlights
  AKT inhibitors, which are most effective in the treatment of tumors characterized
  by AKT genomic alteration but may also possess therapeutic benefit in PI3K hyperactivated
  tumors. mTORC1, dual mTORC1/2, and dual-specificity mTOR/PI3K inhibitors are represented
  in the orange box. Currently several rapalogues are FDA-approved for multiple cancer
  indications.
pmcid: PMC5548615
papertitle: The emerging role of PI3K/AKT-mediated epigenetic regulation in cancer.
reftext: Jennifer M Spangle, et al. Biochim Biophys Acta. ;1868(1):123-131.
pmc_ranked_result_index: '15762'
pathway_score: 0.9105903
filename: nihms862090f2.jpg
figtitle: Emerging role of PI3K/AKT-mediated epigenetic regulation in cancer
year: ''
organisms: Homo sapiens
ndex: 43159903-df09-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5548615__nihms862090f2.html
  '@type': Dataset
  description: PI3K/AKT pathway hyperactivation represents a viable therapeutic modality
    in cancer. The blue box indicates PI3K inhibitors with preclinical and/or clinical
    activity. Non-selective, “pan” PI3K inhibitors target all class I PI3K isoforms
    and p110α-selective inhibitors are biologically active against tumors with p110α
    hyperactivation through upstream RTK activation or direct p110α mutational activation.
    P110β-selective inhibitors are efficacious in the treatment of tumors characterized
    by PTEN genomic alteration, and the p110δ-selective inhibitor Idelalisib is effective
    in blocking PI3K-mediated B cell receptor signaling and is FDA approved for the
    treatment of relapsed chronic lymphoid leukemia (CLL). The purple box highlights
    AKT inhibitors, which are most effective in the treatment of tumors characterized
    by AKT genomic alteration but may also possess therapeutic benefit in PI3K hyperactivated
    tumors. mTORC1, dual mTORC1/2, and dual-specificity mTOR/PI3K inhibitors are represented
    in the orange box. Currently several rapalogues are FDA-approved for multiple
    cancer indications.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - RICTOR
  - PIK3CB
  - RPTOR
  - MTOR
  - MLST8
  - PIK3R6
  - PIK3R5
  - MAPKAP1
  - PIK3CD
  - PIK3R3
  - PIK3CA
  - AKT3
  - PIK3R4
  - AKT2
  - PIK3CG
  - AKT1
  - AZD8186
  - Temsirolimus
  - GSK690693
  - BEZ235
  - MLN0128
  - AZD6482
  - AZD2014
  - Sirolimus
genes:
- word: MTORC1/2
  symbol: mTORC2
  source: bioentities_symbol
  hgnc_symbol: RICTOR
  entrez: '253260'
- word: P13K/MTORinhibitors
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: (mTORC1
  symbol: mTORC1
  source: bioentities_symbol
  hgnc_symbol: RPTOR
  entrez: '57521'
- word: MTORC1/2
  symbol: mTORC2
  source: bioentities_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: MTORC1/2
  symbol: mTORC2
  source: bioentities_symbol
  hgnc_symbol: MLST8
  entrez: '64223'
- word: (mTORC1
  symbol: mTORC1
  source: bioentities_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: P13K/MTORinhibitors
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: P13K/MTORinhibitors
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: MTORC1/2
  symbol: mTORC2
  source: bioentities_symbol
  hgnc_symbol: MAPKAP1
  entrez: '79109'
- word: P13K/MTORinhibitors
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: P13K/MTORinhibitors
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: MTOR
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: P13K/MTORinhibitors
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: P13K/MTORinhibitors
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: P13K/MTORinhibitors
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
chemicals:
- word: AZD8186
  source: MESH
  identifier: C000595972
- word: Temsirolimus
  source: MESH
  identifier: C401859
- word: GSK690693
  source: MESH
  identifier: C528328
- word: BEZ235
  source: MESH
  identifier: C531198
- word: MLN0128
  source: MESH
  identifier: C572449
- word: AZD6482
  source: MESH
  identifier: C578518
- word: AZD2014
  source: MESH
  identifier: C585537
- word: Sirolimus
  source: MESH
  identifier: D020123
diseases: []
figid_alias: PMC5548615__F2
redirect_from: /figures/PMC5548615__F2
figtype: Figure
---
